The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder
暂无分享,去创建一个
A. Heintz‐Buschart | P. Wilmes | W. Oertel | B. Mollenhauer | C. Trenkwalder | A. Janzen | F. Sixel-Döring | Urvashi Pandey | T. Wicke | Elisabeth Sittig-Wiegand
[1] G. Deuschl,et al. Gut microbiota in Parkinson disease in a northern German cohort , 2017, Brain Research.
[2] Luis Pedro Coelho,et al. Erratum to: Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients , 2017, Genome Medicine.
[3] Anders F. Andersson,et al. Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life , 2017, Front. Microbiol..
[4] James T. Morton,et al. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome , 2017, Movement disorders : official journal of the Movement Disorder Society.
[5] E. Pekkonen,et al. Oral and nasal microbiota in Parkinson's disease. , 2017, Parkinsonism & related disorders.
[6] Luis Pedro Coelho,et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients , 2017, Genome Medicine.
[7] K. Doppler. Hauttest erlaubt frühe Parkinsondiagnose , 2017 .
[8] W. D. de Vos,et al. Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function , 2017, PloS one.
[9] J. Volkmann,et al. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease , 2017, Acta Neuropathologica.
[10] A. Gobert,et al. The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties , 2016, Scientific Reports.
[11] A. Heintz‐Buschart,et al. IMP: a pipeline for reproducible reference-independent integrated metagenomic and metatranscriptomic analyses , 2016, Genome Biology.
[12] F. Scheperjans. Gut microbiota, 1013 new pieces in the Parkinson's disease puzzle. , 2016, Current opinion in neurology.
[13] Rob Knight,et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease , 2016, Cell.
[14] W. D. de Vos,et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice , 2016, Nature Medicine.
[15] P. Wilmes,et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility , 2016, Cell.
[16] K. Fassbender,et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. , 2016, Parkinsonism & related disorders.
[17] T. Dinan,et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. , 2016, Journal of psychiatric research.
[18] A. Heintz‐Buschart,et al. Integrated multi-omics of the human gut microbiome in a case study of familial type 1 diabetes , 2016, Nature Microbiology.
[19] E. Masliah,et al. Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans , 2016, Scientific Reports.
[20] Y. Li,et al. Gut microbiota signatures of longevity , 2016, Current Biology.
[21] M. Ota,et al. Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. , 2016, Journal of affective disorders.
[22] T. Friede,et al. Monitoring of 30 marker candidates in early Parkinson disease as progression markers , 2016, Neurology.
[23] A. Heintz‐Buschart,et al. Identification, Recovery, and Refinement of Hitherto Undescribed Population-Level Genomes from the Human Gastrointestinal Tract , 2016, Front. Microbiol..
[24] G. O’Keeffe,et al. Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms. , 2016, Parkinsonism & related disorders.
[25] J Licinio,et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism , 2016, Molecular Psychiatry.
[26] T. Downing,et al. The metabolism of the non-proteinogenic amino acid β-N-methylamino-L-alanine (BMAA) in the cyanobacterium Synechocystis PCC6803. , 2016, Toxicon : official journal of the International Society on Toxinology.
[27] Morris A. Swertz,et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity , 2016, Science.
[28] B. Maček,et al. Tyrosine 601 of Bacillus subtilis DnaK Undergoes Phosphorylation and Is Crucial for Chaperone Activity and Heat Shock Survival‡ , 2016, Front. Microbiol..
[29] Jun Wang,et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota , 2015, Nature.
[30] K. Ohno,et al. Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson’s Disease , 2015, PloS one.
[31] E. Horváth-Puhó,et al. Vagotomy and subsequent risk of Parkinson's disease , 2015, Annals of neurology.
[32] C. Schadt,et al. PanFP: pangenome-based functional profiles for microbial communities , 2015, BMC Research Notes.
[33] Ali Keshavarzian,et al. Colonic bacterial composition in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[34] M. Gorzelak,et al. Methods for Improving Human Gut Microbiome Data by Reducing Variability through Sample Processing and Storage of Stool , 2015, PloS one.
[35] Bing Ruan,et al. Altered fecal microbiota composition in patients with major depressive disorder , 2015, Brain, Behavior, and Immunity.
[36] B. Mollenhauer,et al. Improved preparation of nasal lavage fluid (NLF) as a noninvasive sample for proteomic biomarker discovery. , 2015, Biochimica et biophysica acta.
[37] R. Dobbs,et al. Peripheral aetiopathogenic drivers and mediators of Parkinson’s disease and co-morbidities: role of gastrointestinal microbiota , 2015, Journal of NeuroVirology.
[38] W. Oertel,et al. A new dopaminergic nigro-olfactory projection , 2015, Acta Neuropathologica.
[39] Jeroen Raes,et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates , 2015, Gut.
[40] Rob Knight,et al. Analysis of composition of microbiomes: a novel method for studying microbial composition , 2015, Microbial ecology in health and disease.
[41] L. Lebrun,et al. Method optimization for fecal sample collection and fecal DNA extraction. , 2015, Biopreservation and biobanking.
[42] W. D. de Vos,et al. Akkermansia muciniphila Adheres to Enterocytes and Strengthens the Integrity of the Epithelial Cell Layer , 2015, Applied and Environmental Microbiology.
[43] Jeffrey L. Curtis,et al. Analysis of the Upper Respiratory Tract Microbiotas as the Source of the Lung and Gastric Microbiotas in Healthy Individuals , 2015, mBio.
[44] Michael W. Taylor,et al. The nasal microbiota in health and disease: variation within and between subjects , 2015, Front. Microbiol..
[45] E. Pekkonen,et al. Gut microbiota are related to Parkinson's disease and clinical phenotype , 2015, Movement disorders : official journal of the Movement Disorder Society.
[46] A. Méjean,et al. Biosynthesis of anatoxin-a and analogues (anatoxins) in cyanobacteria. , 2014, Toxicon : official journal of the International Society on Toxinology.
[47] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[48] P. Bork,et al. LotuS: an efficient and user-friendly OTU processing pipeline , 2014, Microbiome.
[49] C. Bassis,et al. The nasal cavity microbiota of healthy adults , 2014, Microbiome.
[50] Anders F. Andersson,et al. Systematic Design of 18S rRNA Gene Primers for Determining Eukaryotic Diversity in Microbial Consortia , 2014, PloS one.
[51] Alexandros Stamatakis,et al. Metagenomic species profiling using universal phylogenetic marker genes , 2013, Nature Methods.
[52] T. Friede,et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort , 2013, Neurology.
[53] P. Cox,et al. The Non-Protein Amino Acid BMAA Is Misincorporated into Human Proteins in Place of l-Serine Causing Protein Misfolding and Aggregation , 2013, PloS one.
[54] Brian C. Thomas,et al. The human gut and groundwater harbor non-photosynthetic bacteria belonging to a new candidate phylum sibling to Cyanobacteria , 2013, eLife.
[55] Carlos H Schenck,et al. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. , 2013, Sleep medicine.
[56] C Trenkwalder,et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. , 2013, Sleep medicine.
[57] Susan Holmes,et al. phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data , 2013, PloS one.
[58] D. Devos,et al. Colonic inflammation in Parkinson's disease , 2013, Neurobiology of Disease.
[59] H. Shill,et al. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. , 2013, Journal of neuropathology and experimental neurology.
[60] H. Reichmann,et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice , 2012, Scientific Reports.
[61] Paul Wilmes,et al. A biomolecular isolation framework for eco-systems biology , 2012, The ISME Journal.
[62] Katherine H. Huang,et al. Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.
[63] Jeffrey H. Kordower,et al. Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease , 2011, PloS one.
[64] D. Higgins,et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega , 2011, Molecular systems biology.
[65] E. Rizzi,et al. Anatoxin-a Synthetase Gene Cluster of the Cyanobacterium Anabaena sp. Strain 37 and Molecular Methods To Detect Potential Producers , 2011, Applied and Environmental Microbiology.
[66] H. Shill,et al. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders , 2010, Acta Neuropathologica.
[67] Paramvir S. Dehal,et al. FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments , 2010, PloS one.
[68] D. Mash,et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease , 2009, Acta neurologica Scandinavica.
[69] K. Chaudhuri,et al. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.
[70] K. Jellinger. Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders , 2009, Acta Neuropathologica.
[71] J. Jankovic,et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.
[72] Y. Jeon,et al. Biosynthetic Intermediate Analysis and Functional Homology Reveal a Saxitoxin Gene Cluster in Cyanobacteria , 2008, Applied and Environmental Microbiology.
[73] Rick L. Stevens,et al. The RAST Server: Rapid Annotations using Subsystems Technology , 2008, BMC Genomics.
[74] H. Braak,et al. Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.
[75] H. Braak,et al. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology , 2006, Neuroscience Letters.
[76] R. Bidigare,et al. Diverse taxa of cyanobacteria produce beta-N-methylamino-L-alanine, a neurotoxic amino acid. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[77] J. Cummings,et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.
[78] Johan Marinus,et al. Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUT , 2004, Movement disorders : official journal of the Movement Disorder Society.
[79] L. Durso,et al. Measurements of Fitness and Competition in Commensal Escherichia coli and E. coli O157:H7 Strains , 2004, Applied and Environmental Microbiology.
[80] P. Cox,et al. Occurrence of β‐methylamino‐l‐alanine (BMAA) in ALS/PDC patients from Guam , 2004, Acta neurologica Scandinavica.
[81] Korbinian Strimmer,et al. APE: Analyses of Phylogenetics and Evolution in R language , 2004, Bioinform..
[82] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[83] K. Bloch,et al. German Version of the Epworth Sleepiness Scale , 1999, Respiration.
[84] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[85] K. Walters,et al. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study , 2015, The Lancet Neurology.
[86] Jens Roat Kultima,et al. Disentangling the effects of type 2 diabetes and metformin on the human gut microbiota , 2015, Nature.
[87] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[88] Siegfried Gauggel,et al. Validität und Reliabilität einer deutschen Version der Geriatrischen Depressionsskala (GDS) , 1999 .
[89] A. Schmidtke,et al. [Studies of the reliability and validity of the German version of the Montgomery-Asberg Depression Rating Scale (MADRS)]. , 1988, Schweizer Archiv fur Neurologie und Psychiatrie.